Why Sanofi’s Lantus SoloStar still anchors many diabetes routines

Insulin glargine in the Lantus SoloStar pen is not flashy, but for many people with type 1 and type 2 diabetes it sets the quiet baseline of the day. What the prefilled pen delivers, where it is strong, and where newer rivals pull ahead.

Reviewed: ad hoc news Software & Services desk. Edited and checked on 2026-06-18, 22:01. Details in the imprint.

With the Lantus SoloStar pen, Sanofi puts a slim white cylinder into the hand that quietly decides how stable the next 24 hours of blood sugar will be. The long-acting insulin glargine in this disposable pen aims for a flat, predictable curve that feels unspectacular in the best possible way.

How Lantus SoloStar works

Lantus SoloStar contains insulin glargine 100 units/ml, a basal insulin designed to release slowly over roughly 24 hours after subcutaneous injection. The insulin forms micro-precipitates in the tissue, from which small amounts dissolve steadily into the bloodstream.

The prefilled pen delivers doses from 1 to 80 units in 1-unit steps, with a dial that clicks firmly under the thumb. For many users that mechanical feedback is the small reassurance before bed that the basal shot is really set.

Daily use, strengths and limits

In everyday use the SoloStar pen feels deliberately simple. The beige and purple markings are clear, the large dose window is easy to read, and the fixed needle position means fewer moving parts when hands are tired at night. That straightforward handling has made SoloStar a workhorse in clinics.

Compared with NPH insulins, Lantus glargine shows fewer pronounced peaks and less night-time hypoglycemia in many patients, according to clinical data. For people who remember shaky nights on older insulins, that calmer profile can be a quiet but convincing upgrade.

Competition from newer basals

On the other side of the chart, newer basal insulins like Sanofi’s own Toujeo (insulin glargine 300 units/ml) and biosimilar glargine products push for even longer action or lower injection volume. They nibble at Lantus’ market share, especially in markets with strong biosimilar uptake.

In India, where Sanofi India promotes Lantus alongside other diabetes therapies, price sensitivity and reimbursement steer many treatment decisions. Lantus often sits as a mid-range, established option rather than the very cheapest vial or the newest premium analogue.

Pricing and availability in India

Sanofi makes Lantus SoloStar available in India as part of packs containing multiple disposable pens, targeting both hospital supply and retail pharmacies. Exact retail prices vary between states and outlets, and are influenced by local trade margins and tenders.

For patients, that usually means a recurring monthly outlay for basal insulin alone, before any rapid-acting insulin or oral drugs are added. Endocrinologists in India therefore often weigh Lantus against human insulin vials where budgets are tighter, even if the analogue profile is medically attractive.

Where it fits in therapy

Lantus glargine is indicated for adults, adolescents and children from 2 years with type 1 diabetes, and adults with type 2 diabetes who require basal insulin. In practice that covers a wide spectrum, from newly diagnosed office workers to long-treated retirees.

Many patients use Lantus once daily in the evening, some in the morning, depending on physician preference and daily routine. For those on intensive therapy, the SoloStar pen becomes the familiar counterweight to a separate rapid-acting insulin before meals.

Investor angle via Sanofi India Ltd

For Sanofi, Lantus SoloStar is no longer the newest star in the diabetes pipeline, but it remains a backbone product in many countries, including India, where Sanofi India Ltd manages a focused portfolio around diabetes and cardiovascular care. Its stable demand profile helps underpin the subsidiary’s cash flows, even as competition intensifies.

Shares of Sanofi India Ltd (INE058A01010) trade on the BSE in Mumbai, giving local investors an indirect way to participate in the diabetes business anchored by products such as Lantus SoloStar.

Key facts on Lantus SoloStar

• Product: Lantus SoloStar
• Manufacturer: Sanofi India Ltd
• Category: Software/Service/Subscription (therapeutic service via insulin therapy)
• Launch: Internationally mid-2000s, introduced in India thereafter
• RRP / Price: Varies by Indian state and pharmacy, typically multi-pen packs in INR
• Availability: Prescription-only, via hospitals and retail pharmacies across India
• Target group: People with type 1 or type 2 diabetes who need long-acting basal insulin
• Highlight / USP: Flat 24-hour basal profile in a simple disposable pen format

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.